Gubra AS 70.55 -1.95% Mkt capEUR - IndustryBiotechnology 005257.KS Green Cross Holdings Corporation 48,300.00 -5.66% Mkt capKRW 731.75B IndustryBiotechnology GMAB.CO Genmab A/S 1,433.50 -0.52% Mkt ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra ...

HORSHOLM, DENMARK / ACCESS Newswire / June 27, 2025 / On Friday, 27 June 2025 at 12:00 am (CEST), an extraordinary general meeting of Gubra A/S (CPH:GUBRA) (the "Company") was held at the Company's ...

This Big Pharma stock is one of the safest bets, according to the Mad Money host, and it plays an attractive dividend to ...

The study utilized mice fed the Gubra Amylin NASH (GAN) diet for 36 weeks. The GAN diet induces metabolic and histopathologic hallmarks of fibrotic NASH (Veidal et al., 2019).

AbbVie licensed Gubra's GUB014295, a Phase 1, long-acting amylin analog, for $350 million upfront and up to $1.875 billion in "biobucks." ...

Strategic R&D investments and acquisitions, including ImmunoGen and Gubra, position AbbVie for continued revenue and EPS growth, making it a compelling long-term buy.

HØRSHOLM, DK / ACCESS Newswire / June 3, 2025 / Gubra (CPH:GUBRA) Notice to convene extraordinary GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND GUBRA A/SCVR NO. 30 51 40 41 To the shareholders ...